Notice of Proposed Sale · 144
Palisade Bio, Inc.
PALINASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- PALISADE BIO, INC.
- Issuer CIK
- 0001357459
- SEC file number
- 001-33672
- Phone
- (858) 704-4900
- Person for whose account securities are to be sold
- Jones Mitchell Lawrence
- Relationships to issuer
- Officer
- Street
- 7750 EL CAMINO REAL, SUITE 5200
- City
- CARLSBAD
- State / country code
- CA
- Postal code
- 92009
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 53,000 | 108,120.00 | 173,580,000 | 07/07/2026 | NASDAQ | Raymond James & Associates |
Broker / market maker — proposed row 1, entry 1
- Name
- Raymond James & Associates
- Street
- 880 Carillon Parkway
- City
- St. Petersburg
- State / country code
- FL
- Postal code
- 33716
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/07/2026 | RSU | issuer | 53,000 | N | 07/07/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
RSU SELL TO COVER FOR TAXES
Notice signature
- Notice date
- 07/07/2026
- Signed
- Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Mitchell Lawrence Jones
Company context
We are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including fibrostenotic Crohn’s disease (“FSCD”) and ulcerative colitis (“UC”).